Bayer AG is in mediation to potentially settle thousands of U.S. lawsuits claiming that the company's Roundup weed killer causes cancer, but some legal experts said the cases raises novel questions that may prevent an easy settlement. According to Reuters,
more than 18,400 plaintiffs claim Roundup causes a type of cancer called non-Hodgkin's lymphoma.
Bayer to date has lost three U.S. jury trials in the Roundup litigation. The company is appealing the decisions, saying Roundup and its active ingredient glyphosate are not carcinogenic and safe for human use.
On July 30, the company said it is "constructively engaging" in talks led by mediator Ken Feinberg. Bayer's chief executive said he would only consider a "financially reasonable" settlement if the company can end all litigation.
Feinberg said mediation was still in the early stages and compensation had not been discussed.
Bayer declined to comment, citing confidentiality agreements in the mediation. Plaintiffs lawyers did not respond to requests for comment.
Legal experts outlined several obstacles the parties may face on the path towards settlement.